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cense. httpAbstract Background: Transcription factors play a crucial role in myeloid differentiation and
lineage determination. Tumor suppressor protein C/EBPa is a key regulator of granulocytic differ-
entiation whose functional inactivation has become a pathophysiological signature of myeloid leu-
kemia. Given the role that CCAAT/enhancer binding protein a (C/EBP a) plays in myelopoiesis, we
anticipated that their expression might be disrupted in myeloid neoplasms.
Purpose: To estimate the expression of C/EBPa mRNA in patients with acute myeloid leukemia
and correlate its expression with the pathogenesis of the disease.
Patients and methods: Forty AML patients and 20 age and sex matched healthy controls were
included in the study. Blood samples of patients and controls were analyzed for CEBPa mRNA
expression by quantitative RT-real time PCR using TaqMan technology & DDCt method for cal-
culation of gene expression.
Results: Twenty-nine (72.5%) patients out of the 40 showed low expression levels of CEBPa
mRNA below the cutoff value with median of 0.19 (range:0–0.87). While eleven (27.5%) patients
out of the 40 showed higher expression levels of CEBPa above the cutoff value with median of
1.52 (range:1.07–2). Seven patients out of the 11 showed higher expression levels of CEBPa mRNA
belong to the M3 subtype of AML harboring the t(15;17) PML–RARa translocation.1227786830.
(N. Kassem).
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Acute myeloid leukemia is the most frequent hematological
malignancy in adults, with an estimated worldwide annual
incidence of three to four cases per 100,000 people. Despite
intensive research for new therapies and prognostic markers,
it is still a disease with a highly variable prognosis among pa-
tients and a high mortality rate. Indeed, less than 50% of adult
AML patients have a 5-year overall survival rate (OS), and, in
the elderly, only 20% survive 2 years [1].
Acute myeloid leukemia (AML) is a cytogenetically and
molecularly heterogeneous disease characterized by clonal
proliferation of myeloid precursors with maturation arrest
of myeloid cells in the bone marrow and impaired produc-
tion of normal blood cells. Thus, the leukemic cell inﬁltra-
tion in marrow is accompanied, nearly invariably, by
anemia and thrombocytopenia. The absolute neutrophil
count may be low or normal, depending on the total white
cell count [2].
C/EBPs are a family of transcription factors that regulate
cell growth and differentiation. These factors, particularly
C/EBPa and C/EBPe, have important roles in normal myelo-
poiesis [3].
C/EBPa is the founding member of a family of basic region/
leucine zipper (bZIP) transcription factors and is a master reg-
ulator of granulopoiesis. It is expressed at high levels through-
out myeloid differentiation and binds to the promoters of
multiple myeloid-speciﬁc genes at different stages of myeloid
maturation [5]. C/EBPa is probably part of a self-reinforcing
pathway that causes myeloid cells to become postmitotic and
to assume the characteristics of mature neutrophils [4].
Target genes of C/EBPa include granulocyte colony stimu-
lating factor (G-CSF) receptor and myeloperoxidase. In addi-
tion, C/EBPa is able to block growth by enhancing the activity
of the cyclin-dependent kinase (cdk) inhibitor p21, inhibiting
E2F transactivation, and blocking cdk2 and cdk4 activity [6,7].
Interaction of transcription factors with other nuclear pro-
teins plays an important role in a combinatorial fashion in
stem cell development, lineage commitment and differentiation
in the hematopoietic system. Besides mutations, C/EBPA pro-
tein function is also disrupted by negative protein–protein
interactions in AML. In many of those AML cases that are
associated with chromosomal translocation, the resulting
translocation product disrupts the expression and function of
the same lineage factor and the regulatory proteins key to
the maintenance of normal hematopoiesis. C/EBPA, being
the key regulator of granulopoiesis, seems to be easily dis-
rupted by these translocations [8,9].
For example, the PML–RARA fusion protein, signature
of acute promyelocytic leukemia (APL), results from the
translocation t(15;17) blocking promyelocytic differentiation
[10]. In primary human APL cells, PML–RARA inhibits
C/EBPA function by down regulating its expression. Also,t(15;17) post-translationally inhibits C/EBPA DNA binding
activity via a mechanism that involves the formation of
the PML/RARA-C/EBPa protein complex. Moreover, over-
expression of C/EBPA in acute promyelocytic leukemia cells
antagonizes the differentiation-inhibitory effect of PML/
RARA [11].
More recently, Tokita and colleagues showed that
RUNX1/EVI1 chimeric transcription factor produced by
t(3;21) causes leukemic transformation in hematopoietic stem
cell tumors, possibly through a differentiation block of malig-
nant myeloid progenitors by associating with C/EBPA and
thereby inhibiting its function [12].
AML with the t(8;21) translocation gives rise to the fu-
sion gene AML1–ETO encoding the AML1–ETO fusion
protein. AML1–ETO appears to suppress C/EBPA expres-
sion indirectly by inhibiting positive autoregulation of the
C/EBPA promotor. In addition, conditional expression of
C/EBPA overcomes the block of differentiation caused by
AML1–ETO and is sufﬁcient to trigger terminal neutrophil-
ic differentiation. Restoring C/EBPA expression will have
therapeutic applications in AML1–ETO-positive Leukemias
[13].
The previous observations raise the possibility that de-
creased expression of C/EBPa might have a role in the patho-
genesis of AML; hence real time PCR was performed to
estimate expression of C/EBPa mRNA in AML patients.
Materials and methods
Participants
After informed patient consent and approval by the Institu-
tional Review Board (IRB), 40 newly diagnosed AML patients
referred to Kasr El Aini Centre of Oncology and Radiation
(NEMROCK) in the period from 2009 to 2011 were studied.
The diagnosis of AML was based mainly on morphological
FAB classiﬁcation. Patients were diagnosed in the Clinical
Pathology department and treated in Clinical Oncology
department, Kasr AL-Aini, Cairo University. Twenty age
and sex matched healthy controls were enrolled in this study.
Ethical approval & Informed consent were obtained from all
participants.
ATRA can induce a complete remission in most patients
with APL. Other FAB subtypes’ patients received induction
therapy; 7+3 protocol. Three days of an anthracycline: (dau-
norubicin, at least 60 mg/m2, idarubicin, 10–12 mg/m2, or the
anthracenedione mitoxantrone, 10–12 mg/m2), 7 days of cyt-
arabine (100–200 mg/m2 continuous IV).
After a median duration of follow up for 6 months, the
overall survival rate: deﬁned from the date of the ﬁrst visit till
the last follow up) and the Disease Free Survival rate (DFS:
deﬁned from the date of CR achievement till the date the pa-
tient relapsed) were assessed.
Table 1 Patients’ characteristics.
Characteristics No = 40
Gender
Male (no, %) 22 (55%)
Female 18 (45%)
Age (years)
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Polymerase chain reaction (PCR)
RNA isolation and cDNA synthesis
Total RNA was extracted from peripheral blood or bone mar-
row blast cells using commercially available extraction kits
(Qiagen, Germany). The amount of RNA was measured
spectrophotometrically. The RNA integrity was tested on the
Nanodrop. All samples had an OD 260/280 nm ratio >1.8,
indicating high purity.
For the generation of ﬁrst strand cDNA, 2 lg of total RNA
was reversed transcribed in a ﬁnal volume of 100 ll with the
high capacity cDNA Archive Kit (Applied Biosystem,
Netherland).
PCR ampliﬁcation
cDNA speciﬁc CEBPa Taqman primer and probe sets were
developed using primer express software. The nucleotide num-
bering throughout this study is based on the published se-
quence available from EMBL/GenBank/DDBJ under
accession number NM_004364.1: The forward primer of CEB-
Pa (50-TCGGTGGACAAGAACAG-30), the reverse primer (50
GCAGGCGGTCATT-30), and the probe ([6-FAM]-ACAA
GGCCAAGCAGCGC-[TAMRA-6-FAM]).
Commercially available primers and probe for reference
GAPDH gene were used for normalization (Applied Biosys-
tems). The probe was labeled with VIC dye and to avoid com-
petition in the PCR reaction tube, the concentrations of
primers were adjusted.
All PCR reactions were performed on the ABI Prism 7700
Sequence Detection System (Applied Biosystems) using the
ﬂuorescent Taqman methodology. The PCR cycle at which
the ﬂuorescence arises above the background signal is called
the Cycle threshold (Ct) and it is inversely proportional to
the log of the initial copy number.
In total 10 ll of the reverse transcription volume was
used for each PCR reaction in a total volume of 50 ll. A
real time PCR reaction was carried out. One primer pair
ampliﬁed the target gene and the other ampliﬁed the endog-
enous reference gene. Primer and probe concentrations for
the target gene were optimized according to the manufac-
turer’s procedure.
For CEBPa mRNA; the concentrations were 15 pmol for
forward and reverse primers and 10 pmol for the probe. The
thermal cycling conditions comprised 10 min at 95 C, 15 s at
95 C (45 cycles of 15 s denaturation at 95 C) and 60 s
annealing at 60 C.Median (range) 30 (12–77)
Hb ({Males: 13–18; females: 12–16} g/dl)
Mean ± SD 7.9 ± 1.88
WBCs ({4–11} · 109/l)
Median (range) 20.000(2300–419000)
Platelets ({150–450} · 109/l)
Median (range) 56.000(6000–99000)
P.B. blasts (%)
Median (range) 23 (4–85)
B.M. blasts (%)
Median (range) 45 (20–90)Statistical analysis
Data showed non-parametric distribution &Mann–Whitney U
test was used for comparisons between two groups. This test is
the non-parametric alternative to Student’s t-test.
Chi-square (v2) test was used for studying the comparisons
and associations between different qualitative variables.
Spearman’s correlation coefﬁcient was used to determine
signiﬁcant correlations between CEBPA expression and differ-
ent variables.
Kaplan–Meier survival curve was constructed for survival
analysis.The signiﬁcance level was set at P 6 0.05. Statistical analy-
sis was performed with IBM/SPSS Statistics Version 20 for
Windows.
Results
Patients characteristics
Characteristics of AML patients are shown in (Table 1).
Results of morphological examination, cytochemical stain-
ing and immunophenotyping performed on peripheral blood
and bone marrow samples showed that the most common sub-
type of AML in our study population according to the FAB
classiﬁcation was 19(47.5%) cases of M3. Nine cases (22.5%)
of M1, 5 cases (12.5%) of M5b, 2 cases (5%) of M5a, 2 cases
(5%) of M0, 2 cases of M2 (5%) and 1 case (2.5%) of M6. No
M7 was seen in our study.
Expression of CEBPa mRNA
DDCt method
To quantify the relative expression of CEBPa mRNA, the Ct
(threshold cycle) values were normalized for endogenous
reference (DCt = Ctsample_CtGAPDH) and compared with a
calibrator, using the ‘delta–delta Ct method’ (DDCt =
DCtSample_Ctcontrol). As calibrator we used the average CEBPa
mRNA Ct value in the 20 P.B and B.M samples of healthy vol-
unteers. Using the DDCt value, the relative expression was cal-
culated (2DDCt) [14].
CEBPa mRNA expression results were classiﬁed into two
subgroups: Low and High expression according to CEBPa
mRNA expression mean level of the healthy population. CEB-
Pa mRNA expression in the healthy population had a mean of
0.97 (considered as cutoff value) using the DDCt method. Low
values below the control mean (<0.97) was considered ‘‘Low’’
expression. High values above the control mean (>0.97) was
considered ‘‘High’’ expression.
The results obtained using this method showed low expres-
sion of CEBPa mRNA in 29 (72.5%) out of the forty patients
(values of CEBPa mRNA expression were below the cutoff)
Figure 1 Comparison between CEBPa mRNA expression in M3
and other FAB subtypes.
118 N. Kassem et al.with median level of 0.19 (range 0–0.87) while the other eleven
patients (27.5%) had higher expression of CEBPa mRNA
(values were above the cutoff) with a median of 1.52 (range
1.07–2).
Comparison between CEBPa mRNA expressions in relation to
FAB subtypes
In cases with all FAB subtypes & M3 subtype; there was a sta-
tistically signiﬁcant difference between cases with low and
higher CEBPa mRNA expression (P-value =<0.001).
M3 Cases showed statistically signiﬁcantly higher
CEBPa mRNA expression values than other FAB subtypes
(P-value = 0.036) (Fig. 1).
Cytogenetics and CEBPa mRNA expression in our study group
In our study population, 6 cases (15%) have positive t(8;21), 4
cases (10%) have positive CEP8 and among 19 cases of M3, 15
(78.9%) have positive t(15;17) and 4 (21.1%) were M3 variant
(hypogranular) subtype with negative t(15;17).
There was no statistically signiﬁcant difference between
CEP8 and t(8;21) distributions in cases with high and low
CEBPa mRNA expression. As regards t(15;17), cases with
higher expression showed statistically signiﬁcantly higher
prevalence of positive t(15;17) than cases with low expression
(Table 2).
CEBPa mRNA expression and response to therapy
Disease free survival (DFS)
When our patients were stratiﬁed according to CEBPA expres-
sion subgroups, it was found that the median DFS of all casesTable 2 Cytogenetics and CEBPa mRNA expression in our study
FISH analysis Low exp
t(8;21) (No. = 40) Positive 4(13.8%
Negative 25(86.2%
t(15;17) (No. = 40) Positive 8(27.6%
Negative 21(72.4%
Cep 8 (No. = 40) Positive 3(10.3%
Negative 26(89.7%
Cep 8, centromere enumeration probe 8.
* Signiﬁcant at P 6 0.05.was 0.17 years, patients with Low CEBPA expression had a
DFS with range of (0.08–4) years and patients with higher
CEBPA expression had DFS with range of (0–2) years and this
was of no statistical signiﬁcance (P= 0.95) (Table 3 & Fig. 2).
Overall survival (OS)
The median OS for all cases was 0.33 years. Low CEBPa
mRNA expression patients had OS with range of (0.08–
4.17) years while patients with Higher CEBPa mRNA expres-
sion had OS with range of (0.17–2.17) years with a high statis-
tical signiﬁcant difference (P= 0.047) (Table 4 and Fig. 3).
Discussion
In the last decade, somatically acquired mutations have been
identiﬁed in several genes in cytogenetically normal (CN)
AML: the nucleophosmin 1 (NPM1) gene, the fms-related
tyrosine kinase 3 (FLT3) gene, the CCAAT/enhancer binding
protein alpha (CEBPA) gene, the myeloid-lymphoid or mixed-
lineage leukemia (MLL) gene, the neuroblastoma RAS viral
oncogene homolog (NRAS) gene, the Wilms tumor 1 (WT1)
gene, and the runt-related transcription factor 1 (RUNX1)
gene [15,16]. These gene mutations are most prevalent in
CN-AML; however, they also occur in AML with abnormal
karyotypes [17].
C/EBPA is a key mediator of normal myeloid differentia-
tion, contributing to both granulopoiesis and monopoiesis.
C/EBPA also inhibits cell cycle progression and stimulates cell
survival. Alterations in the CEBPA gene or in pathways that
down-modulate C/EBPA expression at the transcriptional,
translational, or posttranslational levels likely contribute to
myeloid transformation by inhibiting myeloid differentiation
while favoring myeloid progenitor cell cycle progression [20].
Impairments in C/EBPA signaling such as reduced mRNA
or protein expression, aberrant post translational modiﬁca-
tions (phosphorylation) and the presence of (dominant-
negative) mutations are often observed in human myeloid
leukemias which may subsequently contribute to leukemic
transformation [13]. Mutations in the transcription factor
CCAAT/enhancer binding protein a gene (CEBPA) are found
in 5–14% of the patients with AML [18].
Our study measures only mRNA expression of CEBPA,
which may or may not reﬂect protein expression levels in
AML. We found that there was statistically signiﬁcant differ-
ence between CEBPa mRNA expression where the majority
of patients 29/40 (72.5%) had low CEBPA expression levels
while 11/40 (27.5%) cases showed higher expression levels.
This is in accordance with the results previously reported bygroup.
ression Higher expression P value
) 2(18.2%) 0.729
) 9(81.8%)
) 7(63.6%) 0.035*
) 4(36.4%)
) 1(9.1%) 0.906
) 10(90.9%)
Figure 2 Kaplan–Meier survival curve for DFS data.
Table 4 CEBPa mRNA expression and OS time of our study
population.
CEBPA subgroups OS (years)
Range Median P* value
Low expression 0.08–4.17 0.25 P= 0.047*
Higher expression 0.17–2.17 0.50
* P value is signiﬁcant at the 60.05 level.
Figure 3 Kaplan–Meier survival curve for OS data.
Table 3 CEBPa mRNA expression and DFS time of our
study population.
CEBPA subgroups DFS (Years)
Range Median P* value
Low expression 0.08–4 0.08 P= 0.95
Higher expression 0–2 0.25
* P value is signiﬁcant at the 60.05 level.
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that the majority of their patients showed low CEBPA expres-
sion level [14,19].The CEBPA gene is down-regulated in APL and its up-
stream promoter region is highly methylated. However, the
mechanisms regulating CEBPA expression in APL have not
been completely identiﬁed. The data reported by Guibal
et al. [22], support a role for CEBPA deregulation in APL gen-
esis. In our work, we observed that M3 cases showed statisti-
cally signiﬁcantly higher CEBPA expression values than
other FAB subtypes. This is in agreement with the previously
reported data from Santana-Lemos et al. (2011) who observed
that patients with acute promyelocytic leukemia (M3) pre-
sented with higher levels of CEBPA expression than other
acute myeloid leukemia subtypes [22] and Pabst et al., who re-
ported that acute promyelocytic subtype (M3) of AML is char-
acterized by the presence of the PML–RARA fusion protein
the product of t(15;17) and over expression of C/EBPA [13].
Our 40 patients received induction therapy and were in-
cluded in the survival analysis. Clinical outcome after a median
duration follow up of 6 months was investigated based on
CEBPA expression levels. Higher C/EBPA expression (M3)
correlated with higher OS values compared to low C/EBPA
expressing AML patients.
Conclusion and future directions
Using Real Time PCR, we were capable to deﬁne two main
subgroups of patients with low and high CEBPA m-RNA
expression, although we observed heterogeneous CEBPA
expression among different FAB subtypes. Regarding the
clinical outcome, higher CEBPA expressing patients had better
survival rates, while low expressing patients had poor survival
rates.
Restoration of C/EBPA expression in AML might provide
a means to induce cell differentiation and slow cell prolifera-
tion to contribute to AML therapy [20]. The potential for dif-
ferentiating therapy to improve cure rates in AML is
exempliﬁed by the use of ATRA for the treatment of acute
promylocytic leukemia (APL). High doses of ATRA have
been shown to dissociate the PML–RARA fusion product
associated with RARA-responsive genes, thereby converting
PML–RARA to an activator allowing differentiation to
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